newsfilter
← Latest News
Business Wire·

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

– LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue